CD274 and non-small cell lung carcinoma: For example, the combination of PD-L1 and its overexpression with immune checkpoint inhibitors could be a cost-effective strategy to treat NSCLC with nivolumab as first-line and second-line treatments, as well as with pembrolizumab as first-line [95].